
Experimental DT-109 Reverses Fatty Liver by Targeting Gut Bacteria — Not the Liver
Most experimental treatments for metabolic dysfunction-associated steatohepatitis (MASH), the severe form of fatty liver disease that affects roughly 7% of the global population, target the liver directly, attempting to reduce fat accumulation, inflammation, or fibrosis. A new study from the University of Michigan and collaborators in China takes a fundamentally different approach: fix the gut, […]










